Kornimate/medical-research-clean huggingface dataset:
the comparative effectiveness of alprostadil,sodium ferulate and dopamine in pediatric acute kidney injury

Conditions: Children AKI Patients

Summary: acute kidney injury (aki) is a pervasive clinical event in children.it has been independently associated with prolonged hospital stays, risk of in-hospital death and future progression to chronic kidney disease. except for removal of nephrotoxic agents and optimization of supportive care,there are still no other effective therapeutic options recommended by recent guidelines. renal ischemia is the main mechanism of aki, the improving microcirculation therapy would be the effective management to improve the outcome of aki in children. dopamine is a vasodilating drug that in small doses improves renal circulation. alprostadil have been used in chronic arterial occlusion and sodium ferulate in ischemic cerebral vascular disease,they have a similar therapeutic effect of anti-platelet aggregation and vasodilation. recent research shows that alprostadil might be associated with a significant reduction in postcontrast scr, blood urine nitrogen (bun) and cystatin c (cysc) level and decrease the incidence of contrast-induced nephropathy.the investigators speculate that alprostadil,sodium ferulate and dopamine would be effective in treating aki in children. this is a prospective, multicenter, randomized, double-blind, 52-week study. the purpose of this study is to evaluate the comparative effectiveness and safety of alprostadil,sodium ferulate and dopamine in improving the outcome of aki in children.

this study aims to explore the effective treatment of pediatric aki and improve the outcome. it is a 52-week multicenter, randomized, double-blind,prospective study to evaluate comparative effectiveness and safety of alprostadil injection,sodium ferulate and dopamine injection. this study plans to recruit 8 to 10 centers, with 300 participants randomly divided into 3 groups and given respectively alprostadil 0.2\~0.3ug/kg.h,iv,1h/d,14d,sodium ferulate2\~6mg/kg.d,iv,14d,dopamine3\~5ug/kg .min,iv,3h/d,14d.time of outcome measurement is 1w,2w,4w,24w,52w. primary outcome measures is the change of serum creatinin from baseline, estimated glomerular filtration rate (egfr) and urine volume in the participants after the use of the study drug.

Eligibility criteria:
inclusion criteria: 1. provide informed consent signed and dated by participants and/or their guardians 2. male or female, asian. 3. aged from 1 to 18 years. 4. patients meet the aki diagnosis criteria of 2012 kidney disease: improving global outcome (skdigo) guideline exclusion criteria: 1. prerenal or postrenal failure 2. patients need renal replacement therapy 3. patients with hemorrhagic disorders 4. patients in shock 5. patients with multiple organ failure 6. history of alprostadil or sodium ferulate or dopamine sensitivity 7. patients with heart failure 8. patients with peptic ulcer 9. patients with glaucoma 10. patients with interstitial pneumonia

Keywords: aki child alprostadil sodium ferulate dopamine
awareness among pt regarding sensory integration therapy on cp population

Conditions: Sensory Integration Disorder (Disorder)

Summary: the study is to interrogate the awareness level of physiotherapists that are working in the region of baluchistan, to access weather know about sensory integration therapy or they use it for the patients of cerebral palsy in their treatment plan or not.

the study title is ''awareness among physical therapists of baluchistan regarding effectiveness of sensory integration therapy on cerebral palsy population.' it is a cross-sectional study that will be conducted in the province of baluchistan, pakistan. the data will be conducted by 200 physical therapists on a self designed tool, that will allows us to know about the awareness among the physical therapist of this particular region to know if they are using sensory integration therapy in the treatment plan of the children suffering from cerebral palsy to know weather the sensory issues are being addressed over there by this therapy or not. another purpose of this study is to make the therapists aware about sensory integration therapy and its efficacy in treating sensory processing and sensory integration issues present in the children that are suffering from cerebral palsy. the data will be collected by the physical therapists that are currently working in various hospitals of baluchistan located in different regions of the province.

Eligibility criteria:
inclusion criteria: physical therapists working in province of baluchistan, specifically. exclusion criteria: physical therapists working in areas other than baluchistan.

Keywords: cerebral palsy sensory integration disorder
high-dose l-carnitine and diaphragmatic function assessed by ultrasonography in patients with respiratory failure.

Conditions: Respiratory Failure

Summary: l-carnitine supplementation has been shown to boost muscular performance in several studies. in hemodialysis patients with muscular weakness, fatigue, or cramps/aches, after l-carnitine treatment, about two-thirds of patients had at least some improvement in muscular symptoms . l-carnitine was also found to improve the left ventricular ejection fraction (lvef) in hemodialysis patients with cardiac morbidity who had significantly reduced lvef in echocardiography before supplementation. moreover, l-carnitine has been shown to improve muscular function and exercise performance in athletes in several studies


Eligibility criteria:
inclusion criteria: * age from 21 years old or greater * both genders have respiratory failure either of the primary medical origin or in the post-surgical course. * not in need of mechanical ventilation exclusion criteria: * renal failure on regular dialysis * hypothyroidism * seizures * end-stage liver disease * mechanical ventilation * history or discovered allergy to l-carnitine, pivampicillin, and other pivalate-conjugated antibiotics.
demographics, characteristics and outcomes of male breast cancer patients at methodist health system

Conditions: Ductal Carcinoma in Situ; Invasive Lobular Breast Carcinoma

Summary: to determine the number of mbc cases as well as the demographics, characteristics, and outcomes of mbc patients at methodist health system (mhs).

male breast cancer (mbc) is a rare disease without sufficient clinical data supporting the management and treatment. the treatment of mbc arises from data extrapolated from female breast cancer (fbc). mbc has higher mortality than fbc. previous studies have suggested differences between mbc and fbc; however, treatments remain the same for both. larger studies in mbc are needed to provide more clinical data to help guide treatment.

Eligibility criteria:
inclusion criteria: * • ≥ 18 years of age patients diagnosed with ductal carcinoma in situ or invasive lobular carcinoma of the breast exclusion criteria: * 18 years of age * prisoners * pregnant or breastfeeding
examination of the impact of better surveillance and communication of patient deterioration on patient related outcomes

Conditions: Severe Sepsis; Cardiac Arrest; Respiratory Failure

Summary: a hospitals manual method of patient monitoring will be implemented in an automated system and supported by an early patient deterioration detection for timely escalation. the purpose of this study is to assess if clinical outcomes of patients in acute care are significantly improved by such a system.

the purpose of this study is to assess if the philips intellivue guardian solution (igs) with all its components can significantly improve clinical outcomes for deteriorating patients on a general medical ward prior and after referral to the hospitals' acute care team (act). further, to provide evidence that the philips igs assists to increase the efficiency of a hospital's early warning scoring process (afferent and efferent arm of the escalation system). the introduction of such an intelligent automated system offers a unique opportunity to address the breakdown in the chain of prevention by strengthening the reliability of calls-for-help to responders through a technical solution with the potential for a more timely escalation where appropriate. in this study the hospital's standard of care protocol for the monitoring of vital signs (including timing, vital signs collected and escalation instructions) will be implemented in a commercially available intelligent automatic monitoring and notification system. no investigational procedures or devices are associated with this protocol.

Eligibility criteria:
inclusion criteria: * all patients admitted to the study units during the period of data collection exclusion criteria: * less than 24h on ward

Keywords: patient deterioration rapid response teams acute care teams early warning scoring
iexposure intervention for social anxiety

Conditions: Social Anxiety

Summary: social anxiety (sa) is a highly prevalent mental health concern, thought to disproportionately affect youth with recent international estimates of more than 30% of individuals reporting clinically elevated symptoms. despite the prevalence of sa, as few as one in five individuals receive care, due to limited access to evidence-based treatments. additionally there has been a notable increase in social anxiety since the start of the covid-19 pandemic. this proposal will use iexposure to develop a personalized mechanism-focused approach to optimizing treatment response for individuals with social anxiety by testing standard iexposure against two augmentations that incorporate distinct attention mechanisms (attention guidance and attention control).


Eligibility criteria:
inclusion criteria: * age 18 or older * fluent in english * leibowitz social anxiety scale \> 47 and endorses both social anxiety items on the web screening questionnaire for common mental disorders exclusion criteria: * currently receiving cbt for social anxiety disorder * significant visual impairment precluding engagement in the simulated teleconferencing interactions * unstable dose of psychotropic medications within 6 weeks prior to baseline assessment * current alcohol or substance use disorder * current or past bipolar disorder or psychosis
transumbilical laparoscopy-assisted appendectomy

Conditions: Appendicitis Acute

Summary: transumbilical laparoscopic-assisted appendectomy (tulaa) was reported that the operation time was shorter and the postoperative frequency of complications was not high compared to conventional laparoscopic appendectomy (cla) with three conventional ports in retrospective studies. the purpose of this study is to evaluate the outcomes of transumbilical laparoscopic-assisted appendectomy (tulaa) and to compare them to the outcomes of cla.

single port appendectomy can be considered as the better option than conventional laparoscopic appendectomy (cla) for pediatric patients with uncomplicated acute appendicitis in cosmetic aspect. however, this technique has not gained popularity because it has been regarded as a tricky and time-consuming procedure. recently, the frequency of implementation of transumbilical laparoscopy-assisted appendectomy (tulaa) is increasing in pediatric patients with uncomplicated appendicitis. the reason that this operation is possible in children, is that the length between umbilicus and appendix is shorter than that of an adult, and the abdominal wall is flexible, so that the appendix can be extracted through umbilical incision. it was reported that the operation time was shorter and the postoperative frequency of complications was not high compared to the laparoscopic appendectomy with three conventional ports. the purpose of this study is to evaluate the outcomes of transumbilical laparoscopic-assisted appendectomy (tulaa) and to compare them to the outcomes of cla.

Eligibility criteria:
inclusion criteria: * patients with clinically diagnosed as acute appendicitis * age 18 or under * lab tests hemoglobin ≥ 10g/dl white blood cell count ≥ 4,000/mm3 platelet count ≥ 100,000/mm3 creatinine ≤ 1.5 mg/dl aspartate aminotransferase ≤ 100 iu/l alanine aminotransferase ≤ 100 iu/l * no significant dysfunction in the heart, lungs, kidneys. exclusion criteria: * previous abdominal operation * generalized peritonitis * anticipated extended resection * periappendiceal abscess on preoperative exam
tmi with hd mel in asct for r/r multiple myeloma (bmt-03)

Conditions: Multiple Myeloma, Relapsed; Multiple Myeloma, Refractory to Standard Treatment

Summary: in this phase i trial, patients with relapsed or refractory multiple myeloma will receive standard autologous stem cell transplant conditioned with high dose melphalan. in addition to melphalan, the conditioning will include targeted total marrow irradiation (tmi). this is a conventional 3+3 phase i trial with increasing doses of tmi from minimum 3gy to maximum 9gy.

in this phase i trial, patients with relapsed or refractory multiple myeloma will receive standard high dose melphalan with autologous stem cell rescue. in addition the pre-transplant conditioning will include targeted total marrow irradiation (tmi). this conventional 3+3 phase i trial will increase the dose of tmi until the maximum tolerated dose (mtd) is reached. initial patients enrolled will receive the lowest possible dose of 3gy. maximum dose will be 9gy.

Eligibility criteria:
inclusion criteria: 1. patients meeting criteria for symptomatic myeloma 2. patients who have progressive myeloma following initial induction (patients may have received any number of treatment regimens including prior autologous transplant) 3. patient age 18-75 years at time of enrollment 4. karnofsky performance status of ≥70 5. cardiac function: lvef \>40% 6. hepatic: bilirubin \<2x upper limit of normal and alt and ast \< 2.5x the upper limit of normal 7. renal: creatinine clearance of \>30ml/min, estimated or calculated 8. pulmonary: dlco, fev1, fvc \>50% of predicted (after correction for hemoglobin) exclusion criteria: 1. patients with diagnosis of plasma cell leukemia 2. patients with truly non secretory myeloma (patients with light chain disease are eligible) 3. pregnant or breast-feeding 4. uncontrolled viral, fungal or bacterial infection note: infection is permitted if there is evidence of response to medication. eligibility of hiv infected patients will be determined on a case-by-case basis. 5. patients who have undergone prior allogeneic stem cell transplant 6. prior solid organ transplant 7. patients receiving prior radiation to more than 20% of bone marrow containing areas

Keywords: multiple myeloma relapsed refractory progressive disease symptomatic
the effectiveness of an exclusive cold snare polypectomy snare for the removal of diminutive colorectal polyps

Conditions: Diminutive Colorectal Polyp; Cold Snare Polypectomy; Polypectomy Snare; Complete Resection Rate; Postpolypectomy Bleeding

Summary: the use of an exclusive cold polypectomy snare enables a clean cut of diminutive colorectal polyps, resulting in an increase in the complete resection rate and a decrease in the adverse events.


Eligibility criteria:
inclusion criteria: * patients with colorectal polyps up to 10 mm in diameter. exclusion criteria: * patients are less than 20 years old, pregnant, asa class iii and iv, allergic to propofol used or its components (soybeans or eggs), with poor bowel preparation, and with previous colorectal surgical resection.
efficacy of spinal cord stimulation in patients with a failed back surgery syndrome.

Conditions: Back Pain; Spinal Cord Stimulation

Summary: when patients suffer from chronic pain after multiple back surgeries, this is denominated as the 'failed back surgery syndrome'. a possible treatment for these patients is spinal cord stimulation. this is an invasive treatment where no other treatment options (medication, minimal invasive treaments) can offer progress to the patients' health status. in spinal cord stimulation, an electrode will be placed at the spinal cord under local anaesthesia whereas via a battery a painless electrical stimulation will arise. clinical research have demonstrated that a new way of spinal cord stimulation can improve back and leg pain significantly. this will lead to a better quality of life for the patients and a decreased use of medications. in ziekenhuis oost-limburg, different manners of spinal cord stimulation will be compared to each other.

the patients in our pain centre are implanted with medtronic material. this material cannot deliver the 10khz frequency but can deliver up to 5000 hz (hereinafter referred to as high density stimulation). this also delivers high energy to the spinal cord without palpable paresthesia, with a beneficial effect on the pain. we wish to include patients who, in accordance with belgian regulations, have undergone a normal evaluation period with an external battery and who have subsequently had a definitive system implanted. the implant procedure, evaluation period and the material used are identical to patients outside the study context. we wish to compare different stimulation modes within a patient population in which an epidural electrode for failed back surgery syndrome (fbss) has been implanted, in order to evaluate the effectiveness. we will evaluate the modality "high-density", conventional stimulation and sham stimulation in the same patient. this can be easily adjusted by reprogramming the implanted battery. for this study we want to use a relatively new study design, namely: single case design (n-of-1 trial). in this, many variables will be evaluated with a limited number of study subjects in order to determine an effect. we want to investigate to what extent the patient experiences the different stimulation modes and to what extent he can compare or prefer these stimulation modes. the stimulation that the patient prefers as most pleasant can be continued afterwards. if the patient does not experience pain reduction during a certain stimulation mode, he can always fall back on his own pain medication.

Eligibility criteria:
inclusion criteria: * patients with an implanted neurostimulation system met een fbss met geïmplanteerd exclusion criteria: * no knowledge of the dutch language * addicted to drugs
single arm clinical trial (gut microbiota and hcc)

Conditions: Liver Cancer

Summary: to evaluate the efficacy and safety of oral enterobacterial capsules in patients with intermediate and advanced hcc who have progressed after treating with immune checkpoint inhibitors in combination with anti-angiogenesis targeted agents.

this is a prospective, single-center, single-arm clinical study. for those who meet the enrollment conditions, the original regimen of immune checkpoint inhibitors combined with anti-angiogenic targeted drugs will remain unchanged after enrollment.on this basis, the study subjects started oral enterobacterial capsules to see whther enterobacterial capsules could improve the efficacy of patients receiving the above treatment regimens. oral administration of intestinal bacteria capsules 6 capsules/day, after observing no adverse reactions, oral administration for 10 consecutive days, 6 capsules/day from the second day to the tenth day, and then discontinued to the next course of treatment. total course of treatment: a total of 4 courses of oral intestinal bacteria capsules, each course of oral administration for 10 days, and a course of 21 days; a course of tki combined with immune checkpoint inhibitors treatment is 21 days until the disease progresses or intolerable toxicity and side effects appear. observe the metrics: primary clinical endpoint - progression-free survival (pfs); secondary clinical endpoints - overall growth phase (os), objective response rate (orr), duration of response (dor), and disease control rate (dcr). the new recist1.1 criteria were used for the efficacy evaluation system, the ctcae5.0 grading system was used for the evaluation of common adverse reactions during treatment, and other indicators included imaging including conventional biochemical indexes such as ct and ultrasound, as well as quality of life scores.

Eligibility criteria:
inclusion criteria: 1. age 18-75 years old, gender is not limited; 2. confirmed imaging or histological diagnosis of unresectable hcc, bclc stadium b or c; 3. clinical diagnosis of hcc progression during tkis combined with icis treatment; 4. not suitable for local ablation or chemoembolization; 5. child-pugh grade a; 6. ≥ 1 measurable lesion (recist v1.1) 7. ecog ps 0-1 exclusion criteria: 1. usage of antibiotics within 2 weeks prior enrollment; 2. diagnosis of immunodeficiency (e.g. hiv, immunosuppressants) 3. patients with known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation; 4. female patients who are pregnant or breastfeeding; 5. patients with untreated acute or chronic active hepatitis b or hepatitis c infection. 6. patients are currently undergoing clinical trials of other drugs; 7. patients are considered by the investigator to be unsuitable for inclusion.
tygris - row: tysabri global observational program in safety - rest of world

Conditions: Multiple Sclerosis

Summary: the primary objective of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (saes) in participants with multiple sclerosis (ms) treated with tysabri (natalizumab).

the tysabri global observational program in safety for rest of world (tygris - row)is a safety observational cohort program designed to obtain long-term safety data in multiple sclerosis (ms) participants treated with tysabri in a clinical practice setting in countries other than the united states and canada. the prescribing physician will collect participant information at routine clinic visits (using standard data collection tools) at approximately 6-month intervals for 5 years from the first tysabri infusion.

Eligibility criteria:
key inclusion criteria: * all multiple sclerosis (ms) participants in rest of world (row) who are prescribed and receiving tysabri in normal clinical practice at centers that are taking part in the study are eligible to participate in tygris - row. participants must have received at least 1 and not more than 3 infusions of tysabri. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: tygris - rest of world (row) tysabri natalizumab multiple sclerosis